RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)

Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances.

New Britain, PA June 25, 2025 --(PR.com)-- NeThrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. The RESCUE-II Study was a single-center, prospective study evaluating the safety and feasibility of OTT pharmaco-mechanical lysis (PML) without postprocedural infusion when treating patients with acute intermediate-risk PE. 9 patients were enrolled and successfully treated with low dose r-tPA (4mg per pulmonary artery) using the BEC. At 48 hours, the mean ...